Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $146
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $140 to $146.
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $140 to $146.